A new study by investigators at Shriners Hospitals for Children — St. Louis suggests the damaging effects of obesity are not due to body weight but rather come from something much smaller – biochemical signals released by fat cells, reported the hospital system.
The study focuses on the link between overweight or obesity and the development of osteoarthritis, a painful disease of the joints. The investigation was led by Farshid Guilak, PhD., director of the St. Louis Shriners Hospital Research Center.
“We’ve shown here that it’s not overloading of the joints that is responsible for osteoarthritis, but, more likely, a factor given off by fat cells that makes cartilage susceptible to degeneration,” said Guilak, who also serves as the Mildred B. Simon Professor of Orthopaedic Surgery at Washington University, a partner of the St. Louis Shriners Hospital.
While historically regarded as an unavoidable part of aging, osteoarthritis is now appearing more commonly in children. This is due in part to widespread increases in childhood obesity, coupled with injuries that commonly occur in adolescents, such as knee ligament tears. Little scientific research had been done in the past on the connection between obesity and osteoarthritis because, Guilak said, it was simply dismissed as a byproduct of overloading the joints with increased body weight. But the new study by investigators at the St. Louis Shriners Hospital and the Washington University School of Medicine shows that weight gain alone isn’t the cause.
The study was published in the journal Proceedings of the National Academy of Sciences. It was designed and executed by the lead author Kelsey Collins, Ph.D., a postdoctoral fellow in Guilak’s laboratory.
“This study demonstrates that factors outside of the knee joint can affect cartilage health, which opens the door for a wide range of new osteoarthritis treatment targets we can investigate,” Collins said. “Once we identify the factors given off by fat cells that are responsible for these effects on the joint, we hope to develop new drugs to target them.”
